Showing results (121-130 of 178) with videos related to
Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket studyMatthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.British Journal of Cancer|August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumoursChristophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Circulating CD14<sup>high</sup> CD16<sup>low</sup> intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progressionMélissa Prat, Augustin Le Naour, Kimberley Coulson, et al.Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.American Journal of Clinical Oncology|February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 StudyRoger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.Pageof 18